Expression of the microtubule-associated protein 2 (MAP2) as a potential independent prognostic marker in prostate cancer

J Cancer Res Clin Oncol. 2024 Feb 4;150(2):76. doi: 10.1007/s00432-023-05579-0.


Purpose: Investigation of Microtubuli-associated Protein 2 (MAP2) expression and its clinical relevance in prostate cancer.

Material and methods: MAP2 expression was immunohistochemically analysed on radical prostatectomy specimens using whole block sections (n = 107) and tissue microarrays (TMA; n = 310). The staining intensity was evaluated for carcinoma, benign tissue and prostatic intraepithelial neoplasia. Expression data were correlated with clinicopathological parameters and biochemical recurrence-free survival. Additionally, MAP2 protein expression was quantitatively analysed in the serum of histologically confirmed prostate carcinoma patients and the control group using a commercial enzyme-linked immunosorbent assay.

Results: MAP2 staining was significantly stronger in neoplastic tissue than in non-neoplastic prostatic glands, both in whole block sections (p < 0.01) and in TMA sections (p < 0.05). TMA data revealed significantly stronger MAP2 staining in high-grade tumors. Survival analysis showed a significant correlation between strong MAP2 staining in carcinoma and shortened biochemical recurrence-free survival after prostatectomy (p < 0.001). Multivariate Cox regression analysis confirmed MAP2 as an independent predictor for an unfavourable course. Mean MAP2 serum levels for non-PCA vs. PCA patients differed significantly (non-PCA = 164.7 pg/ml vs. PCA = 242.5 pg/ml, p < 0.001).

Conclusion: The present data support MAP2 as a novel biomarker in PCA specimens. MAP2 is correlated with tumor grade and MAP2 high-expressing PCA is associated with an increased risk of biochemical recurrence after radical prostatectomy. Future studies are necessary to evaluate MAP2 as a valuable immunohistochemical biomarker in preoperative PCA diagnostic procedures, in particular with regard to treatment modalities.

Keywords: MAP2; Prostate carcinoma; Prostatic intraepithelial neoplasia.

MeSH terms

  • Biomarkers
  • Biomarkers, Tumor / metabolism
  • Carcinoma* / surgery
  • Humans
  • Male
  • Microtubule-Associated Proteins
  • Prognosis
  • Prostatectomy / methods
  • Prostatic Neoplasms* / pathology


  • Biomarkers
  • Microtubule-Associated Proteins
  • Biomarkers, Tumor
  • MAP2 protein, human